These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38835349)

  • 21. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.
    Tao JJ; Castel P; Radosevic-Robin N; Elkabets M; Auricchio N; Aceto N; Weitsman G; Barber P; Vojnovic B; Ellis H; Morse N; Viola-Villegas NT; Bosch A; Juric D; Hazra S; Singh S; Kim P; Bergamaschi A; Maheswaran S; Ng T; Penault-Llorca F; Lewis JS; Carey LA; Perou CM; Baselga J; Scaltriti M
    Sci Signal; 2014 Mar; 7(318):ra29. PubMed ID: 24667376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?
    Menendez JA; Lupu R
    Breast Cancer Res; 2007; 9(5):111. PubMed ID: 17983482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular pathways: HER3 targeted therapy.
    Gala K; Chandarlapaty S
    Clin Cancer Res; 2014 Mar; 20(6):1410-6. PubMed ID: 24520092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers.
    Bon G; Loria R; Amoreo CA; Verdina A; Sperduti I; Mastrofrancesco A; Soddu S; Diodoro MG; Mottolese M; Todaro M; Stassi G; Milella M; De Maria R; Falcioni R
    Oncotarget; 2017 Dec; 8(65):108463-108479. PubMed ID: 29312543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-cancer effect of metformin by suppressing signaling pathway of HER2 and HER3 in tamoxifen-resistant breast cancer cells.
    Kim J; Lee J; Kim C; Choi J; Kim A
    Tumour Biol; 2016 May; 37(5):5811-9. PubMed ID: 26581908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.
    Torka R; Pénzes K; Gusenbauer S; Baumann C; Szabadkai I; Őrfi L; Kéri G; Ullrich A
    Neoplasia; 2014 Apr; 16(4):301-18. PubMed ID: 24862757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
    Dey N; Williams C; Leyland-Jones B; De P
    Am J Transl Res; 2015; 7(4):733-50. PubMed ID: 26064441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.
    Kol A; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Lamberts LE; Bensch F; de Vries EG; Schröder CP
    Pharmacol Ther; 2014 Jul; 143(1):1-11. PubMed ID: 24513440
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual targeting of HER3 and EGFR in colorectal tumors might overcome anti-EGFR resistance.
    Temraz S; Mukherji D; Shamseddine A
    Crit Rev Oncol Hematol; 2016 May; 101():151-7. PubMed ID: 27017409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the HER3 pseudokinase domain with small molecule inhibitors.
    Colomba A; Claus J; Gao F; George R; Fornili A; Cameron AJM
    Methods Enzymol; 2022; 667():455-505. PubMed ID: 35525551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. hMENA(11a) contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells.
    Trono P; Di Modugno F; Circo R; Spada S; Di Benedetto A; Melchionna R; Palermo B; Matteoni S; Soddu S; Mottolese M; De Maria R; Nisticò P
    Oncogene; 2016 Feb; 35(7):887-96. PubMed ID: 25961924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
    Sergina NV; Rausch M; Wang D; Blair J; Hann B; Shokat KM; Moasser MM
    Nature; 2007 Jan; 445(7126):437-41. PubMed ID: 17206155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel tumor inhibitory hybridoma monoclonal antibody with dual specificity for HER3 and HER2.
    Hassani D; Amiri MM; Mohammadi M; Yousefi P; Judaki MA; Mobini M; Golsaz-Shirazi F; Jeddi-Tehrani M; Shokri F
    Curr Res Transl Med; 2021 May; 69(2):103277. PubMed ID: 33639587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.
    Lazrek Y; Dubreuil O; Garambois V; Gaborit N; Larbouret C; Le Clorennec C; Thomas G; Leconet W; Jarlier M; Pugnière M; Vié N; Robert B; Monnet C; Bouayadi K; Kharrat H; Mondon P; Pèlegrin A; Chardès T
    Neoplasia; 2013 Mar; 15(3):335-47. PubMed ID: 23479511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study.
    Trinder A; Ding K; Zhang J
    Curr Med Chem; 2024 Jan; ():. PubMed ID: 38231075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.